Protein Kinase N Family Negatively Regulates Constitutive Androstane Receptor-mediated Transcriptional Induction of Cytochrome P450 2b10 in the Livers of Mice

Atsushi Kawase¹, Hideyuki Mukai², Shunsuke Tateishi¹, Shintaro Kuroda¹, Akira Kazaoka¹, Ryosuke Satoh⁴, Hiroaki Shimada¹, Reiko Sugiura⁴,⁵,⁶, and Masahiro Iwaki¹,⁵,⁶*

¹Department of Pharmacy, Faculty of Pharmacy, Kindai University, 577-8502 Osaka, Japan
²Biosignal Research Center, Kobe University, 657-8501 Hyogo, Japan
³Department of Clinical Laboratory, Kitano Hospital, 530-8480 Osaka, Japan
⁴Department of Pharmaceutical Sciences, Faculty of Pharmacy, Kindai University, 577-8502 Osaka, Japan
⁵Pharmaceutical Research and Technology Institute, Kindai University, 577-8502 Osaka, Japan
⁶Antiaging Center, Kindai University, 577-8502 Osaka, Japan

* Corresponding authors.

Masahiro Iwaki and Hideyuki Mukai contributed equally to this study.
Corresponding author: Masahiro Iwaki, Ph.D., Department of Pharmacy, Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, 577-8502 Osaka, Japan
E-mail: iwaki@phar.kindai.ac.jp, Tel: +81-6-4307-3626, Fax: +81-6-6730-1394

Hideyuki Mukai, Ph.D., Department of Clinical Laboratory, Kitano Hospital, 530-8480 Osaka, Japan, and Biosignal Research Center, Kobe University, 657-8501 Hyogo, Japan
E-mail: mukinase@kobe-u.ac.jp, Tel: +81-78-803-6467, Fax: +81-78-803-5782

Running Title
Transcriptional Regulation of Cyp2b10 by Protein Kinase N

The number of text pages: 48
The number of tables: 1
The number of figures: 6
The number of references: 65
The number of words in the Abstract: 248
The number of words in the Introduction: 682
The number of words in the Discussion: 1415
Metabolism, Transport, and Pharmacogenomics

**ABBREVIATIONS:**

PKN, protein kinase N; PKC, protein kinase C; PKA, protein kinase A; D, double-mutant; WT, wild-type; EGFR, epidermal growth factor receptor; P450, cytochrome P450; AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; PXR, pregnane X receptor; BNF, β-naphthoflavone; PB, phenobarbital; TCPOBOP, 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene; DEX, dexamethasone; PHE, phenacetin; DIC, diclofenac; BUP, bupropion; TES, testosterone; SKI-1, Src kinase inhibitor 1; RT-PCR, reverse transcription-polymerase chain reaction; LC-MS/MS, liquid chromatography-tandem mass spectrometry; SRM, selected reaction monitoring; m/z, mass to charge ratio; $V_{max}$, maximum reaction velocity; $K_m$, Michaelis constant; SE, standard deviation; CCRP, cytoplasmic CAR retention protein; HSP, heat shock protein; RXR, retinoid X receptor; EGF, epidermal growth factor; RACK1, receptor for activated C kinase 1; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase kinase; PP2A, protein phosphatase 2A; PBREM, phenobarbital-responsive enhancer module; PCN, pregnenolone-16α-carbonitrile; AMPK, AMP-activated protein kinase; PPAR-α, peroxisome proliferator-activated receptor-α
Key words
protein kinase, cytochrome P450, nuclear receptor, transcriptional regulation

ABSTRACT

In receptor-type transcription factors-mediated cytochrome P450 (P450)s induction, few studies have attempted to clarify the roles of protein kinase N (PKN) in the transcriptional regulation of P450s. This study aimed to examine the involvement of PKN in the transcriptional regulation of P450s by receptor-type transcription factors, including the aryl hydrocarbon receptor, constitutive androstane receptor (CAR), and pregnane X receptor. The mRNA and protein levels, and metabolic activity, of P450s in the livers of wild-type (WT) and double-mutant (D) mice harboring both PKN1 kinase-negative knock-in and PKN3 knockout mutations [PKN1\textsuperscript{T778A/T778A}; PKN3\textsuperscript{−/−}] were determined following treatment with activators for receptor-type transcription factors. mRNA and protein levels, and metabolic activity, of CYP2B10 were significantly higher in D mice treated with the CAR activator phenobarbital (PB), but not with 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene, compared with WT mice. We examined the CAR-dependent pathway regulated by PKN following PB treatment, because the extent of CYP2B10 induction in WT and D mice was notably different in response to treatment with different CAR activators. The mRNA levels of Cyp2b10 in primary hepatocytes from WT and D mice treated with PB alone or in combination with SKI-1 (a Src inhibitor), or U0126 (a
MEK inhibitor), were evaluated. Treatment of hepatocytes from D mice with the combination of PB with U0126, but not SKI-1, significantly increased the mRNA levels of Cyp2b10 compared with those from the corresponding WT mice. These findings suggest that PKN may have inhibitory effects on the Src-RACK1 pathway in the CAR-mediated induction of Cyp2b10 in mice livers.

**Significance Statement**

This is the first report of involvement of PKN in the transcriptional regulation of P450s. The elucidation of mechanisms responsible for induction of P450s could help optimize the pharmacotherapy and improve drug development. We examined whether the mRNA and protein levels, and activities of P450s were altered in double-mutant mice harboring both PKN1 kinase-negative knock-in and PKN3 knockout mutations. PKN1/3 negatively regulates CAR-mediated induction of Cyp2b10 through phosphorylation of a signaling molecule in the Src-RACK1 pathway.
Introduction

Protein kinases regulate various proteins involved in the proliferation, infiltration, and metastasis of cancer cells via phosphorylation (Itoh et al., 1999; Raffetto et al., 2006; Santel et al., 2010; Steelman et al., 2011), and account for approximately 60% of molecular targets for cancer drugs. Protein kinase N (PKN) is a serine/threonine-protein kinase with a catalytic domain that is highly homologous to that of protein kinase C (PKC) at its C-terminal region; three repeats of an antiparallel coiled-coil finger domain; and a C2-like domain at its N-terminal region (Maesaki et al., 1999; Mukai, 2003). In mammals, PKN exists in three subtypes (PKN1/PKNα/PRK1/PAK1, PKN2/PRK2/PAK2/PKNγ, and PKN3/PKNβ). mRNA of PKN1, PKN2, and PKN3 is expressed ubiquitously in the brain, liver, lung, spleen, kidney, heart, intestine, testis, and skeletal muscle (Mukai et al., 2016). Compared to classical protein kinases, such as protein kinase A (PKA) and PKC, the physiological roles of PKN have not been clarified; however, our group and others have identified some physiological roles for this protein kinase (Mukai et al., 2016; Quétier et al., 2016; Danno et al., 2017; Mashud et al., 2017; Uehara et al., 2017). To elucidate the detailed physiological roles of PKN, newly generated double-mutant (D) mice harboring both PKN1 kinase-negative knock-in and PKN3 knockout mutations \([PKN1^{T778A/T778A}; PKN3^{−/−}]\) were used in this study. D mice developed into fertile adults and were morphologically indistinguishable from their wild-type (WT) counterparts.
Conversely, PKN2 knockout mice are not viable due to lethality by embryonic day 10.5. The previous report suggested that PKN were activated by Rho family GTPases, fatty acid, 3-phosphoinositide-dependent kinase 1, and mammalian target of rapamycin, or cleavage by caspase 3 like protease (Mukai, 2003). In the association between epidermal growth factor receptor (EGFR) signal and PKN, it has been reported that the internalization of EGFR is regulated by PKN1 (Gampel et al., 1999).

The expression of cytochrome P450 (P450)s, which is involved in the oxidative metabolism of various endogenous and exogenous compounds, is modulated by genetic variations between individuals and in response to drugs (Sheweita, 2000; McGraw and Waller, 2012). Drug–drug interactions can result in the induction or inhibition of P450s expression. Previous studies have demonstrated that P450s are regulated by kinases on many levels, including transcriptional regulation, protein degradation, and the cellular signaling (Ding and Staudinger, 2005; Oesch-Bartlomowicz and Oesch, 2008; Wang et al., 2009; Müller et al., 2017; Che and Dai, 2018; Smutny et al., 2021). Receptor-type transcription factors such as aryl hydrocarbon receptor (AhR), and nuclear receptor gene superfamily such as constitutive androstane receptor (CAR, NR1I3), and pregnane X receptor (PXR, NR1I2), predominantly regulate the transcription of P450s. CAR and PXR are classified as nuclear receptors. The functions of receptor-type transcription factors are modulated by phosphorylation. For example, the
phosphorylation of AhR is required to activate AhR function after treatment with AhR ligands, such as β-naphthoflavone (BNF) (Long et al., 1998; Schrenk, 1998; Lemaire et al., 2004). Stimulating cells with CAR activators such as phenobarbital (PB, an indirect activator of CAR) and 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene (TCPOBOP, a direct CAR ligand in mice), leads to the translocation of CAR from the cytoplasm to the nucleus following dephosphorylation of the CAR complex (Kawamoto et al., 1999; Tzameli et al., 2000; Yoshinari et al., 2003; Numazawa et al., 2005). The transcriptional regulation of P450s are negatively regulated by PXR phosphorylation (Ding and Staudinger, 2005; Lin et al., 2008; Lichti-Kaiser et al., 2009; Staudinger et al., 2011). Activation of PXR by ligands, such as dexamethasone (DEX), upregulates the transcription of target P450s (Down et al., 2007; Scheer et al., 2010). However, it is unclear whether PKN participates in the transcriptional and/or post-translational regulation of P450s expression and activity via the activation of receptor-type transcription factors.

This prompted us to clarify the roles of PKN in the transcriptional regulation of P450s expression by AhR, CAR, and PXR. We examined the mRNA and protein levels, and metabolic activity of P450s in the livers of D mice treated with BNF, PB, TCPOBOP, and DEX. We chose the P450s involved in the metabolism of xenobiotics, such as drugs, because these P450s are important for elucidating drug-drug interactions.
Materials and Methods

**Chemicals and reagents.** BNF, phenacetin (PHE), acetaminophen, corn oil, and Sepasol-RNA I Super G were purchased from Nacalai Tesque (Kyoto, Japan). PB, DEX, diclofenac (DIC), protease inhibitor cocktail, and Williams’ Medium E were obtained from Sigma-Aldrich (St. Louis, MO, USA). Fast SYBR Green Master Mix, BCA protein assay kit, and GlutaMAX supplement I were obtained from Life Technologies (Carlsbad, CA, USA). MS-grade porcine pancreatic trypsin, bupropion (BUP), testosterone (TES), and collagenase type I were purchased from Wako Pure Chemicals (Osaka, Japan). TCPOBOP and 6β-hydroxy TES were obtained from Cayman Chemical (Ann Arbor, MI, USA). 4-hydroxy BUP and DIC-d4 were purchased from Toronto Research Chemicals (Toronto, Canada). 4′-hydroxy DIC was obtained from Daiichi Pure Chemicals (Tokyo, Japan). Src kinase inhibitor 1 (SKI-1) and U0126 were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Bond Elut C18 was obtained from Agilent Technologies (Santa Clara, CA, USA). ReverTra Ace was obtained from Toyobo Life Science (Osaka, Japan). Oligonucleotide primers were from Eurofins (Luxembourg, Luxembourg). All other chemicals and solvents were of MS grade or the highest commercially available purity.
Animals and treatments. Male WT and D mice of C57BL/6 genetic background, between 10–14 weeks of age, were used in this study. PKN1 knock-in mice lacking kinase activity were generated by introducing a T778A point mutation in the catalytic domain, as described previously (Mashud et al., 2017). PKN3 knockout mice were generated as described previously (Mukai et al., 2016). Double mutant [PKN1T778A/T778A; PKN3−/−] mice were generated by mating PKN1 knock-in mice with PKN3 knockout mice. The mice were housed in an air-conditioned room at 22 ± 0.5°C and relative air humidity of 55 ± 10% with a 12 h lighting schedule (7:00 a.m.–7:00 p.m.) and free access to standard laboratory food (MF; Oriental Yeast Co., Ltd., Tokyo, Japan). Mice were treated with BNF (200 mg/kg, i.p., corn oil), PB (100 mg/kg, i.p., saline), TCPOBOP (3 mg/kg, i.p., corn oil), and DEX (75 mg/kg, i.p., corn oil) (Petrick and Klaassen, 2007). Activators for receptor-type transcription factors or vehicles (10 mL/kg) such as corn oil for BNF, TCPOBOP, and DEX and saline for PB were injected daily at 4:00 p.m. for 4 days. The different mice were used as control animals for each activator. Animals were anesthetized with isoflurane 24 h after the last treatment, and the liver was perfused with ice-cold saline and then removed. After flash freezing in liquid nitrogen, each sample was preserved at −80°C until use for RNA extraction and microsome preparation. The protocol was approved by the Committee for the Care and Use of Laboratory Animals of the Faculty of Pharmacy of Kindai University (Osaka, Japan).
Determination of mRNA levels by real-time reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted from mouse livers using Sepasol-RNA I Super G. mRNA levels were measured by RT-PCR using SYBR Green as described previously (Kawase et al., 2008, 2013). PCR was performed under the following conditions: 40 cycles of 95°C for 10 s, 55°C for 10 s, and 72°C for 30 s. The primer sequences for target gene are listed in Table 1. Data were analyzed using the multiplex comparative method with StepOne Software (Thermo Fisher Scientific, Waltham, MA, USA). The internal control, β-actin was used to normalize gene expression.

Preparation of liver microsomes. Liver microsomes from WT and D mice were prepared as described previously (Uno et al., 2008). Briefly, the homogenized liver was centrifuged at 12,000 × g for 20 min, followed by 105,000 × g for 60 min, to obtain a microsomal pellet. Protein concentrations were determined using a BCA protein assay kit (Life Technologies).

Determination of the metabolic activity of Cyp1a, Cyp2b, Cyp2c, and Cyp3a in liver microsomes. The metabolic activity of liver microsomes was evaluated by the formation of metabolites of typical P450 substrates, as described previously (Uno et al., 2008). PHE
O-deethylation activity was used to probe for CYP1A. BUP 4-hydroxylation activity was
determined as a probe for CYP2B. DIC 4′-hydroxylation activity was determined as a probe for
CYP2C. TES 6β-hydroxylation activity was determined as a probe for CYP3A. The initial
concentrations of substrates in microsomal incubations containing 100 μg protein of
microsomes were: 100 μM of PHE; 20, 100, 200, and 500 μM of BUP; 10 μM of DIC; and 100
μM of TES. The reaction mixtures were incubated for 20 min for BUP and TES, 30 min for
PHE, and 40 min for DIC. These incubation times were within the linear range of enzymatic
activity determined in preliminary assays. The internal standards were DIC for PHE, and BUP,
TES, and DIC-d4 for DIC. Sample clean-up was performed by solid-phase extraction using
Bond Elut C18 (Agilent Technologies, Santa Clara, CA, USA). Aliquots (30 μL) were injected
onto the liquid chromatography-tandem mass spectrometry (LC-MS/MS) system consisting of
an LC system (UltiMate 3000 series, Thermo Fisher Scientific) and a TSQ Endura Triple
Quadrupole Mass Spectrometer with electrospray ionization (Thermo Fisher Scientific). The
analysis was performed using a reverse-phase column (COSMOSIL 5C18-MSII, 4.6 × 150
mm, 5 μm; Nacalai Tesque). The column temperature was set at 40°C, and the autosampler was
maintained at 4°C. The mobile phase (8.5 mM ammonium acetate and 0.0075% [v/v] formic
acid in water/methanol (50:50, [v/v]) was pumped at a flow rate of 1.0 mL/min. Electrospray
ionization was performed in positive ion mode, under the following conditions: 3500 V spray
voltage, 400°C ion transfer tube temperature, 300°C vaporizer temperature with a nitrogen sheath, and 10 arbitrary units of auxiliary gases. Finnigan Xcalibur software (Thermo Fisher Scientific) was used for data recording and analysis. Quantification was performed using the selected reaction monitoring (SRM) of the transitions (mass to charge ratio (m/z), precursor>product) of acetaminophen (152>110), 4-hydroxy BUP (256>238), 4-hydroxy DIC (312>230), 6β-hydroxy TES (305>269), DIC (296>214), and DIC-d4 (302>220). The areas under the metabolite peaks were normalized by the area under each internal standard. $V_{\text{max}}$ (maximum reaction velocity) and $K_m$ (Michaelis constant) for 4-hydroxy BUP formation were obtained by non-linear least-square regression of the Michaelis-Menten equation using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).

**Determination of P450s expression by LC-MS/MS-based targeted proteomics.**

LC-MS/MS-based targeted proteomics was performed according to previously described methods (Hersman and Bumpus, 2014; Kawase, Tateishi, et al., 2018). Briefly, 50 μg of liver microsomes were digested by trypsin at 37°C for 18 h, after which samples were desalted with Bond Elut C18. Eluted samples were dried under a vacuum at 50°C and resuspended in 100 μL of the initial mobile phase (4.5% acetonitrile with 0.1% formic acid). A 20 μL aliquot of each sample was injected into the LC-MS/MS system. The surrogate amino acids sequences for
targeted proteins, mass to charge ratios of precursor ion and product ion, and collision energy were shown in Supplemental Table 1.

Quantitation of plasma PB concentrations by LC-MS/MS. The plasma PB concentrations 24 hr after PB treatments (100 mg/kg, i.p., saline) to WT and D mice were determined by LC-MS/MS according to modification method (Kawase, Kaneto, et al., 2018). Briefly, a 5-μL plasma was deproteinated by adding 50 μL methanol followed by centrifugation at 2000 × g for 10 min. DIC (5 μL of a 100 μg/mL stock) was added as an internal standard to supernatant, along with 200 μL of dH2O, and 500 μL of ethyl acetate. After evaporation to dryness, the residues were each dissolved in 50 μL of LC mobile phase and filtered with a 0.45-μm Millex-LH filter unit (Millipore, Darmstadt, Germany). Aliquots of 20 μL were injected onto the LC-MS/MS. Analysis was performed using a reversed-phase column (COSMOSIL 5C18-ARII, 2.0 × 150 mm, 5 μm; Nacalai Tesque). Column temperature was set at 40 °C, and the autosampler was maintained at 4 °C. The mobile phase (8.5 mM ammonium acetate and 0.0075% (v/v) formic acid in water/methanol (50:50, v/v)) was pumped at a flow rate of 0.2 mL/min. Electrospray ionization was performed in negative ion mode, under the following conditions: 2500 V spray voltage, 400°C ion transfer tube temperature, 300°C vaporizer temperature with a nitrogen sheath, and 10 arbitrary units of auxiliary gases. Finnigan Xcalibur software was used for data
recording and analysis. Quantification was performed using the SRM of the transitions (m/z, precursor>product, collision energy (V)) of PB (231>188, 18 V), and DIC (294>250, 15 V). The areas under the PB peaks were normalized by the area under DIC.

**Primary culture of hepatocytes and treatments.** Mouse hepatocytes were isolated using a two-step collagenase perfusion method as described previously (Seglen, 1976). Viability, as determined by trypan blue exclusion, was above 90%. Hepatocytes were seeded at $1 \times 10^5$ cells/cm$^2$ on a collagen-coated 24-well plate (Sumitomo Bakelite, Tokyo, Japan) in Williams’ Medium E supplemented with 10% fetal bovine serum, 100 nM insulin, 100 nM dexamethasone, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM GlutaMAX supplement I. After an initial attachment period of 2 h, the medium was replaced with fresh serum-free Williams’ Medium E, with whole supplement and 5 U/mL aprotinin. Hepatocytes were treated with 1 mM PB 1 h after the addition of SKI-1 (a Src inhibitor) or U0126 (a MEK inhibitor) at a concentration of 10 μM. Twenty-four-hours after PB treatment, total RNA was extracted from mouse livers using Sepasol-RNA I Super G. mRNA levels of *Cyp2b10* in each group was measured as described above.
Statistical analysis. Differences in between-group means were analyzed statistically using the Bonferroni test, Dunnett test after analysis of variance, or unpaired Student’s t-test. GraphPad Prism 5 was used for all statistical analyses. Values of $p < 0.05$ were considered to be statistically significant.
Results

*P450 mRNA levels were markedly increased in D mice after PB treatments compared with WT mice*

To confirm the susceptibility of WT and D mice to the P450 inducers, the mRNA levels of P450s were determined following treatment with activators for receptor-type transcription factors (Fig. 1). We investigated the mRNA levels of P450s in the livers of mice treated with BNF (AhR ligand), PB (indirect activator of CAR), TCPOBOP (direct CAR ligand), and DEX (PXR ligand). In a preliminary study, we confirmed little changes of the P450s induction between untreated vs. treated with vehicle control. Although the mean values of P450 mRNA levels were different, the differences in between-group means were not statistically significant.

BNF significantly increased the mRNA levels of *Cyp1a1* and *Cyp1a2* in both WT and D mice. The vehicle treatments had little effect on the mRNA levels of P450s (Fig. 1A). Following PB treatment, the mRNA levels of *Cyp2b10* and *Cyp3a11* were significantly increased in both WT and D mice compared with the control (Fig. 1B). The mRNA levels of *Cyp2c29* and *Cyp2c37* were significantly increased in D, but not WT mice, compared with the control (Fig. 1B). There was a significant increase in the mRNA levels of *Cyp2b10*, *Cyp2c29*, and *Cyp2c37* in D mice treated with PB compared with WT mice treated with PB (Fig. 1B). There was a significant increase in the mRNA levels of *Cyp2b10*, *Cyp2c29*, *Cyp2c37*, and *Cyp3a11* in WT mice.
following treatment with TCPOBOP compared with the control (Fig. 1C). Notably, TCPOBOP, similar to PB, led to a marked increase in the mRNA levels of Cyp2b10 in both WT and D mice. Importantly, there were differences in the induction of Cyp2b10 in D mice relative to WT mice following treatment with different CAR activators. PB, an indirect activator of CAR, significantly increased the mRNA levels of Cyp2b10 in D mice compared with WT mice (Fig. 1B), and TCPOBOP, a direct CAR ligand in mice, increased the mRNA level of Cyp2b10 to a similar extent between WT and D mice (Fig. 1C). The mRNA levels of Cyp2b10 and Cyp3a11, but not Cyp2c29 and Cyp2c37, were increased in both WT and D mice following DEX treatment (Fig. 1D). Expression of Cyp3a11 mRNA was higher in D mice compared with WT mice (Fig. 1D). Taken together, these results demonstrate that P450 mRNA inducibility depending on the type of activators for receptor-type transcription factors was different between WT and D mice.

**P450 protein levels were higher in D mice after PB treatment compared with WT mice**

Changes in the mRNA levels of P450s did not necessarily correspond to changes in the protein expression of P450s. To determine the effects of BNF, PB, TCPOBOP, and DEX on the protein levels of P450s, liver microsomes from WT and D mice were examined in the absence and presence of treatment with these activators (Fig. 2 and Supplemental Tables 2–5). The protein
levels of CYP1A1 in liver microsomes from both WT and D mice significantly increased after BNF treatment (Fig. 2A). The protein levels of CYP1A2 in the liver microsomes of D but not WT mice significantly increased after BNF treatment (Fig. 2A). The protein levels of CYP2B10, CYP2C29, and CYP3A11 in the liver microsomes of D mice were significantly increased after PB treatment (Fig. 2B). The protein levels of CYP2B10 in microsomes from D mice were higher than those in microsomes from WT mice following treatment, similar to the changes in observed Cyp2b10 mRNA levels (Fig. 2B). The protein levels of CYP2B10 and CYP2C29 were increased significantly in the liver microsomes of WT and D mice to a similar extent following treatment of TCPOBOP (Fig. 2C). There were few changes in the protein levels of P450s in the liver microsomes of WT and D mice after DEX treatment (Fig. 2D). Changes in the protein levels of other P450s were smaller compared with those of the marker P450s (Supplemental Tables 2–5). These results suggest that the inducibility of P450s protein as well as mRNA depending on the type of activators for receptor-type transcription factors was different between WT and D mice.

**CYP2B activity was higher in D mice after PB treatment compared with WT mice**

Next, the metabolic activity of PHE O-deethylation by CYP1A after BNF treatment (Fig. 3A); BUP 4-hydroxylation by CYP2B, DIC 4′-hydroxylation by CYP2C, and TES 6β-hydroxylation
by CYP3A after PB treatment (Fig. 3B); BUP 4-hydroxylation by CYP2B after TCPOBOP treatment (Fig. 3C); and TES 6β-hydroxylation by CYP3A after DEX treatment (Fig. 3D) were determined in liver microsomes from WT and D mice. The metabolic activity of PHE O-deethylation after BNF treatment; BUP 4-hydroxylation after PB or TCPOBOP treatment; and TES 6β-hydroxylation after PB treatment were significantly increased in WT and D mice compared with the control (Fig. 3). BUP 4-hydroxylation in D mice was significantly higher than that in WT mice following treatment with PB (Fig. 3B). However, similar induction of BUP 4-hydroxylation was observed in WT and D mice following treatment with TCPOBOP. DIC 4′-hydroxylation after PB treatment, and TES 6β-hydroxylation after DEX treatment were unchanged (Figs. 3B and D). BUP 4-hydroxylation is slightly catalyzed by CYP2D and CYP3A, although BUP 4-hydroxylation activity is widely used as a marker of CYP2B activity (Dickmann et al., 2012; Maximos et al., 2017; Zhou et al., 2017). Therefore, BUP 4-hydroxylation activity reflects the activities of major CYP2B and minor CYP2D and CYP3A. The inducibility of CYP2B mRNA, protein, and activity in D mice was different between PB and TCPOBOP treatments. To clarify the effects of functional PKN1/PKN3 deficiency on the characteristics of CYP2B in liver microsomes from WT and D mice with or without PB or TCPOBOP, Michaelis-Menten kinetics of 4-hydroxy BUP formation by CYP2B were examined following treatment with PB (Fig. 4A) or TCPOBOP (Fig. 4B). $V_{\text{max}}$ values for the formation of
4-hydroxy BUP by CYP2B in WT and D mice after treatment with PB were 2.28 ± 0.68 and 6.13 ± 1.30 nmol/min/mg protein, respectively (p < 0.05). $V_{max}$ values in WT and D mice after treatment with TCPOBOP were 2.36 ± 0.53 and 3.64 ± 0.65 nmol/min/mg protein, respectively. There were no significant changes in the $K_m$ values for 4-hydroxy BUP formation by CYP2B in WT and D mice following treatment with PB or TCPOBOP. $V_{max}$ values in D mice after treatment with PB, but not TCPOBOP, were higher than those in WT mice. Among these control groups, there was no difference between $V_{max}$ and $K_m$ values. These results suggest that differences in CYP2B10 mRNA and protein expression between WT and D mice after PB treatment affect the activity of CYP2B. The plasma concentrations of PB which affect the toxicity and inducibility of P450s were determined. The plasma concentrations of PB 24 hr after i.p. administration to WT and D were 13.9 ± 1.06 μg/ml and 12.7 ± 1.23 μg/ml, respectively.

**mRNA levels of Car-interacting proteins were not altered in WT and D mice regardless of PB or TCPOBOP treatment**

To confirm changes in the mRNA levels of Car and CAR-interacting proteins in WT and D mice with or without CAR activator treatment, the mRNA levels of Car and CAR-interacting proteins were determined in the livers of WT and D mice following treatment with PB or TCPOBOP (Fig. 5). In the cytoplasm, CAR forms in complex with cytoplasmic CAR retention
protein (CCRP) and heat shock protein (HSP)90. Following dissociation of CAR from CCRP and HSP90 by binding of the CAR ligand, CAR is translocated into the nuclear compartment, where it forms a heterodimer with the retinoid X receptor (RXR)α. The mRNA levels of Car, Ccrp, Hsp90, and Rxrα were unchanged in WT and D mice, regardless of PB (Fig. 5A) or TCPOBOP treatment (Fig. 5B). Similar mRNA levels of AhR and Pxr in the livers of WT and D mice with or without PB or TCPOBOP treatments were observed (data not shown). Taken together, these data indicate that differences in the induction of CYP2B10 between WT and D mice after PB treatment may not be due to the changes in CAR-interacting proteins.

Cyp2b10 mRNA levels were higher in hepatocytes from D mice compared with those from WT mice due to inhibition of the MEK-ERK pathway

The involvement of PKN in the CAR-dependent pathway after treatment with PB was examined. This was because differences in the CAR-mediated induction of Cyp2b in WT and D mice were observed following treatment with PB, an indirect activator of CAR, and TCPOBOP, a direct CAR ligand in mice. Inhibition of EGFR signaling with PB leads to CAR activation and subsequent induction of P450s transcription (Fig. 6A) (Li et al., 2009; Mutoh et al., 2013; Kobayashi et al., 2015; Yan et al., 2015; Negishi, 2017). PB promotes the transformation of receptor for activated C kinase 1 (RACK1) from p-RACK, and extracellular signal-regulated
kinase (ERK) from p-ERK, which is followed by translocation of CAR to the nucleus. To clarify the involvement of PKN in the Src-RACK1 and/or MEK-ERK pathways in the CAR-mediated induction of Cyp2b, the mRNA levels of Cyp2b10 in hepatocytes from WT and D mice were determined after treatment with PB alone or in combination with SKI-1 (a Src inhibitor) or U0126 (a mitogen-activated protein kinase kinase (MEK) inhibitor) (Fig. 6B). The relative mRNA levels of Cyp2b10 were increased by PB alone and by the combination of PB with SKI-1 or U0126 compared with the control in both WT and D cells (Fig. 6B). The combination of PB and SKI-1 or U0126 in hepatocytes from D mice significantly elevated the mRNA levels of Cyp2b10 compared with those from WT mice (Fig. 6B). The mRNA levels of Cyp2b10 were higher in hepatocytes from D mice treated with the combination of PB and U0126 compared with those treated with PB alone (Fig. 6B). The combination of PB and SKI-1 in hepatocytes from D mice resulted in a similar induction of Cyp2b10 mRNA to PB alone (Fig. 6B). In preliminary experiments, the treatments of SKI-1 alone or U0126 alone had little impacts on the mRNA levels of Cyp2b10 in hepatocytes from WT and D mice (data not shown).
Discussion

Our present study revealed the roles of PKN in the AhR-, CAR-, and PXR-mediated transcription processes of P450s. Following treatment with activators for receptor-type transcription factors, changes in the expression of marker genes, including *Cyp1a1* (AhR), *Cyp2b10* (CAR), *Cyp3a11* (PXR), and other major P450s were examined in WT and D mice.

The results demonstrated that PKN1 and/or PKN3 negatively affected the Src-RACK1 pathway in the induction of *Cyp2b10* mediated by CAR. Several lines of evidence support the above-mentioned findings. First, PB markedly increased the mRNA and protein levels, and metabolic activity of CYP2B10 in D mice compared to WT mice. Second, TCPOBOP, unlike PB, exhibited little differences in the induction of mRNA, protein, or metabolic activity between WT and D, although both PB and TCPOBOP activated CAR. Finally, inhibition of the MEK-ERK pathway, but not the Src-RACK1 pathway before PB treatment, following PB treatment significantly increased the mRNA levels of *Cyp2b10* in hepatocytes from D mice compared with those from WT mice. To our knowledge, this is the first study that demonstrates the roles of PKN1 and PKN3 in the *in vivo* transcriptional induction of P450s.

Following treatment with the AhR ligand BNF, there was little difference in the mRNA levels of *Cyp1a1* and *Cyp1a2* between WT and D mice (Fig. 1A). PHE O-deethylation activity was observed in WT and D mice following treatment with BNF (Fig. 3), although the protein levels
of CYP1A2 in D mice were significantly increased compared with those in the WT and control D mice (Fig. 2A). These results indicate that PKN had little effect on the induction of *Cyp1a1* and *Cyp1a2* by AhR. Following treatment with the PXR ligand DEX, the relative mRNA and protein levels of P450s were unchanged between WT and D mice (Figs. 1D and 2D), showing that PKN had little effect on the induction of P450s by PXR. Previous studies demonstrated that the phosphorylation of PXR by PKA exerted inhibitory effects on P450 transcription (Ding and Staudinger, 2005; Lichti-Kaiser *et al.*, 2009; Staudinger *et al.*, 2011). However, PKN is likely to have little impact on the transcriptional regulation of P450s via phosphorylation of PXR. Although DEX is widely used as a PXR ligand in mouse studies (Cheng *et al.*, 2005; Buckley and Klaassen, 2009), pregnenolone-16α-carbonitrile (PCN) is a rodent specific and strong ligand of PXR (Guzelian *et al.*, 2006). The further studies using PCN could help elucidate the roles of PKN in PXR-mediated induction of P450. Also, consideration should be given to the differences of induction kinetics and the half-life of mRNA, protein and activity of P450s. Further studies are needed to clarify the involvement of PKN in the induction kinetics of mRNA, protein, and activity of P450s. The similar concentrations of PB in WT and D were observed. The predominantly metabolic enzyme for PB is Cyp2c and the metabolic activities of CYP2C in WT and D treated with PB were unchanged (Fig. 3B). Therefore, the similar extent of PB exposures to WT and D mice could be occurred.
Following treatment with the CAR activator PB and CAR ligand TCPOBOP, there were significant different differences in the induction of CYP2B10 mRNA and protein (Figs. 1A, 1B, 2B, and 2C). The treatment of D mice with PB, an indirect activator of CAR, led to a significant induction of CYP2B10 mRNA and protein expression compared with the corresponding WT mice. In the cytoplasm, CAR forms a complex with CCRP and HSP90. Following the dissociation of CAR from CCRP and HSP90 by the binding of CAR direct ligands such as TCPOBOP, CAR translocates to the nuclear compartment. As shown in Fig. 6A, PB inhibits the binding of epidermal growth factor (EGF) to EGFR, which leads to the translocation of CAR to the nucleus and induction of target P450 transcription (Li et al., 2009; Mutoh et al., 2013; Kobayashi et al., 2015). The phosphorylation of CAR-interacting protein is involved in the translocation of CAR to the nucleus (Shizu et al., 2017). Timsit and Negishi demonstrated that TCPOBOP increased CCRP ubiquitination in human hepatocellular carcinoma HepG2 cells co-expressing CAR (Timsit and Negishi, 2014). Enhanced proteasomal degradation of CCRP leads to increased translocation of CAR to the nucleus. Thus, TCPOBOP acts directly on CAR complexes in the cytoplasm. Dephosphorylation of Thr-38 in the CAR protein is also important for CAR translocation to the nucleus (Kawamoto et al., 1999; Mutoh et al., 2009; Hori et al., 2016); however, CAR translocation to the nucleus for P450s induction is a common process following treatment with PB and TCPOBOP. Furthermore, there was no change in the mRNA
levels of CAR and CAR-interacting proteins (Fig. 5), suggesting that differences in the induction of Cyp2b10 by PB and TCPOBOP were not due to changes in the expression levels of these proteins in WT and D mice. Hence, differences in the induction of Cyp2b10 between WT and D mice following PB treatment could be illustrated by the phosphorylation of signaling molecules upstream of CAR translocation to the nucleus by PKN.

To determine the CAR-dependent pathway of Cyp2b10 induction PKN acts after PB treatment, we examined the mRNA levels of Cyp2b10 in hepatocytes of WT and D mice treated with PB in combination with inhibitors of signaling pathways. The mRNA levels of Cyp2b10 in hepatocytes from D mice were higher than those in hepatocytes from WT mice following treatment with PB. Treatment with a combination of PB and U0126 has been shown to increase Cyp2b10 mRNA levels in primary hepatocytes (Joannard et al., 2006). Inhibition of the MEK-ERK pathway following treatment with PB and U0126 resulted in marked increases in Cyp2b10 mRNA levels in hepatocytes from D mice. There were few differences in Cyp2b10 mRNA levels between hepatocytes from WT and D mice treated with the combination of PB and SKI-1. Based on these results, we believe that PKN could have inhibitory effects on the Src-RACK1 pathway, but not the MEK-ERK pathway. Previous reports from our group and other investigators showed increases in Src activity mediated by PKN3 in vitro (Uehara et al., 2017; Gemperle et al., 2019). Higher Src activity promotes the transformation of p-RACK1
from RACK1, which is linked to the suppressed induction of Cyp2b10 by PB (Fig. 6A). It is also needed to further investigate the effects of the lacking PKN activity on the phosphorylation of RACK1 and ERK after PB treatments. The inhibition of the translocation of CAR to nucleus by inhibitors such as okadaic acid provides support for the roles of PKN in CAR-mediated induction of Cyp2b10, although PKN possibly works the signaling processes before CAR translocation to nucleus. A limitation of our study is the detailed mechanisms of the negative regulation of CAR-mediated induction of Cyp2b10 by PKN1/3, although the results of this study show the possibility of inhibitory effects of PKN on the Src-RACK1 pathway. Further studies are needed to clarify the roles of PKN in the signaling processes of EGF-induced activation of EGFR. A decline in this suppression in D mice could promote the induction of Cyp2b10 by PB. PB treatments modulate functions of PXR, AMP-activated protein kinase (AMPK), hepatocyte nuclear factor-4α, and the peroxisome proliferator-activated receptor-α (PPAR-α) in addition to CAR in the livers of mice (Shindo et al., 2007; Tamasi et al., 2009; Braeuning and Pavek, 2020). Previous report demonstrated that AMPK participated in PB induction of CYP2B via the modulation of CAR activity (Rencurel et al., 2005). The activation of PPAR-α resulted in CYP2B1/2 induction (Shaban et al., 2005). Therefore, there is possibility that PKN is involved in the phosphorylation of AMPK or PPAR-α-associated proteins, because PB is highly non-specific in CAR-mediated transactivation. Further studies are needed to clarify
the roles of PKN in CAR-mediated induction of Cyp2b10. It is unclear whether PKN1 or PKN3 predominantly regulates the CAR-mediated induction of Cyp2b10 following PB treatment. CAR is also involved in the transcriptional regulation of phase II enzymes, such as UDP-glucuronosyltransferase and transporters, which affect drug metabolism, pharmacokinetics, and toxicokinetics (Haouzi et al., 2000; Maher et al., 2005; Shelby and Klaassen, 2006). Therefore, it is important to elucidate the roles of PKN in transcriptionally CAR-regulating proteins in addition to CYP2B10.

In conclusions, to our knowledge, this is the first report on the involvement of PKN in the transcriptional regulation of P450s. Elucidation of the detailed mechanisms of P450s induction could help to optimize pharmacotherapy and improve drug development because P450s induction affects drug efficacy and leads to adverse reactions. PKN1/3 negatively regulates the CAR-mediated induction of Cyp2b10, probably due to the phosphorylation of signaling molecules in the Src-RACK1 pathway.
Authorship Contributions

Participated in research design: Kawase, Mukai, Satoh, Shimada, Sugiura, and Iwaki.

Conducted experiments: Kawase, Tateishi, Kuroda, and Kazaoka

Contributed new reagents or analytic tools: Mukai

Performed data analysis: Kawase, Tateishi, and Kuroda

Wrote or contributed to the writing of the manuscript: Kawase, Mukai, Sugiura, and Iwaki

Declaration of Conflicting Interests

The authors declare no competing interest.
References

Braeuning A, and Pavek P (2020) β-catenin signaling, the constitutive androstane receptor and their mutual interactions, Arch Toxicol.


Dickmann LJ, McBride HJ, Patel SK, Miner K, Wienkers LC, and Slatter JG (2012) Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as


Differences in cytochrome P450 and nuclear receptor mRNA levels in liver and small intestines between SD and DA rats. *Drug Metab Pharmacokinet* **23**:196–206.


Maher JM, Cheng X, Slitt AL, Dieter MZ, and Klaassen CD (2005) Induction of the multidrug resistance-associated protein family of transporters by chemical activators of


Timsit YE, and Negishi M (2014) Coordinated regulation of nuclear receptor CAR by


Footnotes

This work was supported by the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2014–2018 [Grant S1411037].
**Figure Legends**

**Figure 1.** mRNA levels of *Cyp1a1, Cyp1a2, Cyp2b10, Cyp2c29, Cyp2c37,* and *Cyp3a11* in the liver of wild type (WT) and double-mutant (D) mice with or without the treatment with β-naphthoflavone (BNF) (200 mg/kg, *i.p.*, corn oil) (A), phenobarbital (PB) (100 mg/kg, *i.p.*, saline) (B), 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene (TCPOBOP) (3 mg/kg, *i.p.*, corn oil) (C), or dexamethasone (DEX) (75 mg/kg, *i.p.*, corn oil) (D) for 4 days relative to WT-C. The results are expressed as the mean ± standard deviation (SD) of each group (BNF; *n* = 5, PB; *n* = 5–8, TCPOBOP; *n* = 3–5, DEX; *n* = 4–5). Differences in between-group means were analyzed statistically using the Bonferroni test after analysis of variance. Significant differences (* *p* < 0.05, ** *p* < 0.01, and *** *p* < 0.001) between control and activator treatments in WT or D mice were observed. Significant differences (# *p* < 0.05, ## *p* < 0.01, and ### *p* < 0.001) between WT mice treated with activator and D mice treated with activator were observed.

**Figure 2.** Protein levels of CYP1A1, CYP1A2, CYP2B9, CYP2B10, CYP2C29, and CYP3A11 in liver microsomes from WT and D mice with or without treatment with BNF (200 mg/kg, *i.p.*, corn oil) (A), PB (100 mg/kg, *i.p.*, saline) (B), TCPOBOP (3 mg/kg, *i.p.*, corn oil) (C), or DEX (75 mg/kg, *i.p.*, corn oil) (D) for 4 days relative to WT-C. The results are expressed as the mean ± SD of each group (BNF; *n* = 5, PB; *n* = 5, TCPOBOP; *n* = 3–5, DEX; *n* = 4–5). Differences in
between-group means were analyzed statistically using the Bonferroni test after analysis of variance. Significant differences (* \( p < 0.05 \), ** \( p < 0.01 \) and *** \( p < 0.001 \)) between control and activator treatments in WT or D mice were observed. Significant differences (# \( p < 0.05 \)) between WT mice treated with activator and D mice treated with activator were observed.

Figure 3. Metabolic activity of phenacetin (PHE) \( O \)-deethylation after BNF treatment (200 mg/kg, \textit{i.p.}, corn oil) (CYP1A) (A), bupropion (BUP) 4-hydroxylation (CYP2B), diclofenac (DIC) 4′-hydroxylation (CYP2C), and testosterone (TES) 6\( \beta \)-hydroxylation (CYP3A) after PB treatments (100 mg/kg, \textit{i.p.}, saline) (B), BUP 4-hydroxylation (CYP2B) after TCPOBOP treatments (3 mg/kg, \textit{i.p.}, corn oil) (C), and TES 6\( \beta \)-hydroxylation (CYP3A) after DEX treatments (75 mg/kg, \textit{i.p.}, corn oil) (D) for 4 days in the liver microsomes of WT and D mice. The results are expressed as the mean \( \pm \) SD of each group (BNF; \( n = 5 \), PB; \( n = 3–5 \), TCPOBOP; \( n = 3–5 \), DEX; \( n = 4–5 \)). Differences in between-group means were analyzed statistically using the Bonferroni test after analysis of variance. Significant differences (* \( p < 0.05 \), ** \( p < 0.01 \), and *** \( p < 0.001 \)) between control and activator treatments in WT or D mice were observed. Significant differences (# \( p < 0.05 \)) between WT mice treated with activator and D mice treated with activator were observed.
Figure 4. Michaelis-Menten plots for BUP hydroxylation in liver microsomes from WT and D mice following treatment with PB (100 mg/kg, *i.p.*, saline) (A) or TCPOBOP (3 mg/kg, *i.p.*, corn oil) (B) for 4 days. The results are expressed as the mean ± SD of each group (PB; *n* = 4–5, TCPOBOP; *n* = 3–5).

Figure 5. mRNA levels of constitutive androstane receptor (*Car*), cytoplasmic *Car* retention protein (*Ccrp*), heat shock protein (*Hsp*)90, and retinoid X receptor (*Rxr*)α in the liver of WT and D mice with or without treatment with PB (100 mg/kg, *i.p.*, saline) (A) or TCPOBOP (3 mg/kg, *i.p.*, corn oil) (B) for 4 days relative to WT-C. The results are expressed as the mean ± SD of each group (PB; *n* = 4, TCPOBOP; *n* = 3–5).

Figure 6. Inhibition of epidermal growth factor receptor (EGFR) signaling by PB leads to CAR activation and subsequent P450s induction (A). PB inhibits epidermal growth factor (EGF)-EGFR binding following the transformation of receptors for activated C kinases (RACK)1 from p-RACK, and extracellular signal-regulated kinase (ERK) from p-ERK (bold arrows). Subsequently, CAR translocates to the nucleus where it promotes the transcription of target P450s, such as Cyp2b10. MEK; mitogen-activated protein kinase kinase, PP2A; protein phosphatase 2A, PBREM; phenobarbital-responsive enhancer module. The mRNA levels of
*Cyp2b10* in hepatocytes from WT and D mice after PB treatment (1 mM) with or without (Src kinase inhibitor (SKI)-1 or U0126) for 24 h (B) relative to controls of WT. Significant differences (*p* < 0.05, **p** < 0.01, and ***p*** < 0.001) were observed. Significant differences from the control of WT or D mice were analyzed by Dunnett test after an analysis of variance. Other significant differences of WT or D mice were assessed by an unpaired Student’s t-test. The results are expressed as the mean ± standard error of each group (*n* = 5–7).
### Tables

#### Table 1. Primer sequences used in polymerase chain reaction (PCR) assays.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyp1a1</td>
<td>Forward  AAGTGCAGATGCGGTCTTCT</td>
</tr>
<tr>
<td></td>
<td>Reverse  GAGCACCCAGAGCACTCTTC</td>
</tr>
<tr>
<td>Cyp1a2</td>
<td>Forward  ATGGCCAGAGCATGATTTTC</td>
</tr>
<tr>
<td></td>
<td>Reverse  GGGAAAGTTCTTTCCAAAGC</td>
</tr>
<tr>
<td>Cyp2b10</td>
<td>Forward  TGGAGATGTGTTCACAGTGC</td>
</tr>
<tr>
<td></td>
<td>Reverse  TTGAAGGTGGCTCAACGAC</td>
</tr>
<tr>
<td>Cyp2c29</td>
<td>Forward  ACAGGAAAACGGATTTGTGC</td>
</tr>
<tr>
<td></td>
<td>Reverse  ATCCCTGATAGGGAGGGATG</td>
</tr>
<tr>
<td>Cyp2c37</td>
<td>Forward  AAGAGGAAGACGGCAATCAA</td>
</tr>
<tr>
<td></td>
<td>Reverse  CTGTTGGGATGAGGTCAAT</td>
</tr>
<tr>
<td>Cyp3a11</td>
<td>Forward  ACAACAAGCAGGGATGGAC</td>
</tr>
<tr>
<td></td>
<td>Reverse  CTCTGGGTCTGTGACAGCAA</td>
</tr>
</tbody>
</table>
**Car**  Forward: ACAGACCCGGAGTTACCCAA  
Reverse: CAGAAACCGACTTTGGAGCC

**Ccrp**  Forward: TGAACTGCTGGAGGACGAAGA  
Reverse: AACCGTCCAAGCATCATCAG

**Hsp90**  Forward: GCTCCTTCGCTATCACACCT  
Reverse: TTGCTCTTTGCTCTCACCAGT

**Rxra**  Forward: ACACCAAACATTTCCTGCCG  
Reverse: CGACCCGTTGGAGAGTTGAG

**β-actin**  Forward: CATTGCTGACAGGATGCAGAA  
Reverse: CCGATCCACACAGAGTACTTGC
Figure 3

(A) PHE O-deethylation activity (nmol/min/mg protein) for WT-C, WT-BNF, D-C, D-BNF.

(B) BUP 4-hydroxylation activity (nmol/min/mg protein) for WT-C, WT-PB, D-C, D-PB.

(C) DIC 4'-hydroxylation activity (pmol/min/mg protein) for WT-C, WT-PB, D-C, D-PB.

(D) TES 6β-hydroxylation activity (nmol/min/mg protein) for WT-C, WT-PB, D-C, D-PB.
Figure 4

(A) BUP 4-hydroxylation activity (nmol/min/mg protein) against Concentration (μM)

(B) BUP 4-hydroxylation activity (nmol/min/mg protein) against Concentration (μM)
Figure 5

(A) 

Car  

Ccrp  

Hsp90  

Rxra

(B)
Figure 6 (A)
Protein Kinase N Family Negatively Regulates Constitutive Androstan Receptor-mediated Transcriptional Induction of Cytochrome P450 2b10 in the Livers of Mice

Atsushi Kawase, Hideyuki Mukai, Shunsuke Tateishi, Shintaro Kuroda, Akira Kazaoka, Ryosuke Satoh, Hiroaki Shimada, Reiko Sugiura, and Masahiro Iwaki

The Journal of Pharmacology and Experimental Therapeutics

JPET-AR-2021-000790
**Supplemental Table 1.** Surrogate peptide sequences for targeted proteins, mass to charge ratios of precursor ion and product ion, and collision energy.

<table>
<thead>
<tr>
<th>P450</th>
<th>Peptide</th>
<th>Precursor ion (m/z)</th>
<th>Product ion (m/z)</th>
<th>Collision energy (eV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>EAEYLISK</td>
<td>476.8</td>
<td>623.4, 752.4, 823.5</td>
<td>17</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>TFNDNFVLFLQK</td>
<td>743.4</td>
<td>747.5, 894.5, 1008.6</td>
<td>25</td>
</tr>
<tr>
<td>CYP2B9</td>
<td>DYIDTYLLR</td>
<td>586.3</td>
<td>665.4, 780.4, 893.5</td>
<td>20</td>
</tr>
<tr>
<td>CYP2B10</td>
<td>GTVAVVEPTFK</td>
<td>574.3</td>
<td>621.3, 720.4, 819.5</td>
<td>20</td>
</tr>
<tr>
<td>CYP2C29</td>
<td>NISQSFTNFSK</td>
<td>636.8</td>
<td>743.4, 830.4, 958.5</td>
<td>22</td>
</tr>
<tr>
<td>CYP2D10</td>
<td>FGDIAPLNLR</td>
<td>606.8</td>
<td>612.4, 709.4, 780.5</td>
<td>21</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>GIIFNGPTWK</td>
<td>623.8</td>
<td>702.4, 816.4, 963.5</td>
<td>21</td>
</tr>
<tr>
<td>CYP2F2</td>
<td>SQDLLTSLTK</td>
<td>553.3</td>
<td>662.4, 775.5, 890.5</td>
<td>19</td>
</tr>
<tr>
<td>CYP3A11</td>
<td>TWGLFDGQTPLAVTDPETIK</td>
<td>1151</td>
<td>1200, 1297, 1398</td>
<td>37</td>
</tr>
</tbody>
</table>
**Supplemental Table 2.** Protein levels of cytochrome P450 (P450)\textsubscript{s} in liver microsomes from wild-type (WT) and double-mutant (D) mice with or without β-naphthoflavone (BNF) treatment (200 mg/kg, *i.p.*, corn oil) for 4 days relative to controls of WT.

<table>
<thead>
<tr>
<th>P450</th>
<th>WT Control</th>
<th>BNF</th>
<th>D Control</th>
<th>BNF</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>1.00 ± 0.258</td>
<td>18.8 ± 4.57*</td>
<td>0.670 ± 0.510</td>
<td>30.9 ± 13.0***</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>1.00 ± 0.196</td>
<td>2.23 ± 0.551</td>
<td>1.17 ± 0.235</td>
<td>4.42 ± 1.37*** #</td>
</tr>
<tr>
<td>CYP2B9</td>
<td>1.00 ± 0.094</td>
<td>0.902 ± 0.136</td>
<td>1.02 ± 0.097</td>
<td>1.03 ± 0.172</td>
</tr>
<tr>
<td>CYP2B10</td>
<td>1.00 ± 0.131</td>
<td>1.58 ± 0.223</td>
<td>1.09 ± 0.097</td>
<td>2.74 ± 0.881**</td>
</tr>
<tr>
<td>CYP2C29</td>
<td>1.00 ± 0.209</td>
<td>1.53 ± 0.901</td>
<td>2.68 ± 0.316</td>
<td>2.85 ± 0.315</td>
</tr>
<tr>
<td>CYP2D10</td>
<td>1.00 ± 0.216</td>
<td>0.969 ± 0.075</td>
<td>1.06 ± 0.126</td>
<td>0.995 ± 0.202</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>1.00 ± 0.084</td>
<td>1.70 ± 0.702</td>
<td>3.24 ± 0.445</td>
<td>4.59 ± 1.51</td>
</tr>
<tr>
<td>CYP2F2</td>
<td>1.00 ± 0.141</td>
<td>0.981 ± 0.252</td>
<td>2.35 ± 0.235</td>
<td>1.97 ± 0.493</td>
</tr>
<tr>
<td>CYP3A11</td>
<td>1.00 ± 0.287</td>
<td>1.31 ± 0.243</td>
<td>1.88 ± 0.454</td>
<td>3.73 ± 0.408***</td>
</tr>
</tbody>
</table>
The results are expressed as the mean ± SD of each group (n = 3–5). Differences in between-group means were analyzed statistically using the Bonferroni test after analysis of variance.

Significant differences (*p < 0.05, **p < 0.01, and ***p < 0.001) between control and BNF treatments in WT or D mice were observed. Significant differences (#p < 0.05) between WT and D mice treated with BNF were observed.
**Supplemental Table 3.** Protein levels of P450s in liver microsomes from WT and D mice with or without phenobarbital (PB) treatment (100 mg/kg, *i.p.*, saline) for 4 days relative to controls of WT.

<table>
<thead>
<tr>
<th>P450</th>
<th>WT Control</th>
<th>WT PB</th>
<th>D Control</th>
<th>D PB</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>1.00 ± 0.354</td>
<td>1.57 ± 0.510</td>
<td>1.09 ± 0.077</td>
<td>2.48 ± 0.971</td>
</tr>
<tr>
<td>CYP2B9</td>
<td>1.00 ± 0.694</td>
<td>1.27 ± 0.311</td>
<td>1.25 ± 0.270</td>
<td>2.29 ± 0.677</td>
</tr>
<tr>
<td>CYP2B10</td>
<td>1.00 ± 0.629</td>
<td>55.7 ± 9.38**</td>
<td>1.47 ± 0.512</td>
<td>97.0 ± 22.6*** #</td>
</tr>
<tr>
<td>CYP2C29</td>
<td>1.00 ± 0.600</td>
<td>2.01 ± 0.520</td>
<td>1.55 ± 0.762</td>
<td>3.30 ± 0.738*</td>
</tr>
<tr>
<td>CYP2D10</td>
<td>1.00 ± 0.182</td>
<td>1.01 ± 0.134</td>
<td>1.04 ± 0.194</td>
<td>1.12 ± 0.192</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>1.00 ± 0.323</td>
<td>0.819 ± 0.251</td>
<td>1.04 ± 0.156</td>
<td>0.658 ± 0.207</td>
</tr>
<tr>
<td>CYP2F2</td>
<td>1.00 ± 0.374</td>
<td>0.843 ± 0.194</td>
<td>1.06 ± 0.379</td>
<td>0.644 ± 0.126</td>
</tr>
<tr>
<td>CYP3A11</td>
<td>1.00 ± 0.281</td>
<td>1.86 ± 0.303</td>
<td>0.941 ± 0.367</td>
<td>3.37 ± 1.84*</td>
</tr>
</tbody>
</table>

The results are expressed as the mean ± SD of each group (n = 3–5). Differences in between-group means were analyzed statistically using the Bonferroni test after analysis of variance.
Significant differences (* $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$) between control and PB treatments in WT or D mice were observed. Significant differences (# $p < 0.05$) between WT and D mice treated with PB were observed.
**Supplemental Table 4.** Protein levels of P450s in liver microsomes from WT and D mice with or without 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene (TCPOBOP) treatment (3 mg/kg, *i.p.*, corn oil) relative to controls of WT.

<table>
<thead>
<tr>
<th>P450</th>
<th>WT Control</th>
<th>TCPOBOP</th>
<th>D Control</th>
<th>TCPOBOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>1.00 ± 0.255</td>
<td>1.73 ± 0.403*</td>
<td>1.39 ± 0.133</td>
<td>1.51 ± 0.201</td>
</tr>
<tr>
<td>CYP2B9</td>
<td>1.00 ± 0.265</td>
<td>1.35 ± 0.340</td>
<td>0.786 ± 0.196</td>
<td>1.29 ± 0.184</td>
</tr>
<tr>
<td>CYP2B10</td>
<td>1.00 ± 0.247</td>
<td>20.6 ± 6.21***</td>
<td>1.27 ± 0.111</td>
<td>20.5 ± 3.28***</td>
</tr>
<tr>
<td>CYP2C29</td>
<td>1.00 ± 0.306</td>
<td>2.29 ± 0.670</td>
<td>1.20 ± 0.434</td>
<td>2.67 ± 0.355**</td>
</tr>
<tr>
<td>CYP2D10</td>
<td>1.00 ± 0.104</td>
<td>0.859 ± 0.192</td>
<td>0.902 ± 0.168</td>
<td>0.852 ± 0.134</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>1.00 ± 0.233</td>
<td>0.718 ± 0.054</td>
<td>0.836 ± 0.112</td>
<td>0.740 ± 0.133</td>
</tr>
<tr>
<td>CYP2F2</td>
<td>1.00 ± 0.046</td>
<td>0.716 ± 0.065*</td>
<td>0.762 ± 0.100</td>
<td>0.567 ± 0.082</td>
</tr>
<tr>
<td>CYP3A11</td>
<td>1.00 ± 0.117</td>
<td>3.29 ± 0.979*</td>
<td>1.56 ± 0.665</td>
<td>2.27 ± 0.585</td>
</tr>
</tbody>
</table>

The results are expressed as the mean ± SD of each group (n = 3–5). Differences in between-group means were analyzed statistically using the Bonferroni test after analysis of variance.
Significant differences (* $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$) between the control and TCPOBOP treatments in WT or D mice were observed.
**Supplemental Table 5.** Protein levels of P450s in liver microsomes from WT and D mice with or without dexamethasone (DEX) treatment (75 mg/kg, i.p., corn oil) for 4 days relative to controls of WT.

<table>
<thead>
<tr>
<th>P450</th>
<th>WT Control</th>
<th>WT DEX</th>
<th>D Control</th>
<th>D DEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>1.00 ± 0.209</td>
<td>0.957 ± 0.275</td>
<td>0.915 ± 0.177</td>
<td>1.07 ± 0.303</td>
</tr>
<tr>
<td>CYP2B9</td>
<td>1.00 ± 0.085</td>
<td>0.585 ± 0.111</td>
<td>1.04 ± 0.257</td>
<td>0.725 ± 0.274</td>
</tr>
<tr>
<td>CYP2B10</td>
<td>1.00 ± 0.172</td>
<td>1.23 ± 0.214</td>
<td>0.923 ± 0.105</td>
<td>1.61 ± 0.427*</td>
</tr>
<tr>
<td>CYP2C29</td>
<td>1.00 ± 0.323</td>
<td>0.880 ± 0.347</td>
<td>0.690 ± 0.313</td>
<td>0.852 ± 0.201</td>
</tr>
<tr>
<td>CYP2D10</td>
<td>1.00 ± 0.172</td>
<td>1.23 ± 0.214</td>
<td>0.923 ± 0.105</td>
<td>1.61 ± 0.427*</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>1.00 ± 0.337</td>
<td>1.46 ± 0.403</td>
<td>1.01 ± 0.437</td>
<td>1.13 ± 0.219</td>
</tr>
<tr>
<td>CYP2F2</td>
<td>1.00 ± 0.240</td>
<td>0.631 ± 0.500</td>
<td>0.602 ± 0.335</td>
<td>0.567 ± 0.269</td>
</tr>
<tr>
<td>CYP3A11</td>
<td>1.00 ± 0.320</td>
<td>1.61 ± 0.393</td>
<td>0.843 ± 0.272</td>
<td>1.51 ± 0.158</td>
</tr>
</tbody>
</table>

The results are expressed as the mean ± SD of each group (n = 3–5). Differences in between-group means were analyzed statistically using the Bonferroni test after analysis of variance.
Significant differences (* $p < 0.05$) between control and DEX treatments in WT or D mice were observed.